title: Retrospective analysis of prognosis for scirrhous-type gastric cancer: one institution's experience.
abstract: BACKGROUND
  Scirrhous gastric cancer is biologically aggressive, and the prognosis is poor even with curative surgery. We compared outcomes with different therapies in order to identify prognostic factors.
  
  
  METHODS
  Records for 83 patients, who were treated between 1991 and 2004, were evaluated for survival and stage, treatment, and clinicopathological factors.
  
  
  RESULTS
  Cumulative 5-year overall survival was 10.2% for all 83 patients, including 27 (32.5%) patients with stage II/III disease and 56 (67.4%) with stage IV disease. The 5-year overall survival rate and median survival time for patients with stage II/III disease after curative surgery were 24.3% and 1150 days. For patients with stage IV disease, 2-year and 5-year survival rates after initial surgery were 13.7% and 0% and median survival was 250 days. In contrast, preoperative chemotherapy for advanced, unresectable disease produced 2-year and 3-year overall survival rates of 53.6% and 26.8% and medican survival was 910 days.
  
  
  CONCLUSIONS
  Aggressive surgery alone does not seem to improve outcome, but preoperative chemotherapy might be beneficial and should be investigated further.
authors: Department of Surgery, School of Medicine, Keio University, Shinanomachi 35, Shinjuku-ku, Tokyo, 160-8582, Japan.
authors: Rieko
authors: R
authors: Nakamura
authors: Yoshiro
authors: Y
authors: Saikawa
authors: Norihito
authors: N
authors: Wada
authors: Masashi
authors: M
authors: Yoshida
authors: Tetsuro
authors: T
authors: Kubota
authors: Koichiro
authors: K
authors: Kumai
authors: Masaki
authors: M
authors: Kitajima
mesh_terms: D002293:Adenocarcinoma, Scirrhous / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D016019:Survival Analysis; D016896:Treatment Outcome
references: Ann Surg Oncol. 1997 Apr-May;4(3):209-14
references: 9142381
references: J Surg Oncol. 1995 Feb;58(2):112-7
references: 7844980
references: Surg Gynecol Obstet. 1992 Jul;175(1):13-6
references: 1621194
references: Oncol Rep. 2003 Mar-Apr;10(2):381-6
references: 12579276
references: Surgery. 1989 Oct;106(4):758-62; discussion 762-3
references: 2552599
references: J Surg Oncol. 1997 Jul;65(3):194-200
references: 9236929
references: Gastric Cancer. 1998 Dec;1(1):10-24
references: 11957040
references: Dig Dis Sci. 1992 May;37(5):757-63
references: 1563320
references: Hepatogastroenterology. 2005 Jan-Feb;52(61):314-8
references: 15783058
references: Br J Cancer. 2003 Dec 15;89(12):2207-12
references: 14676796
references: Am J Surg. 2004 Sep;188(3):327-32
references: 15450843
references: Gastric Cancer. 2003;6 Suppl 1:40-4
references: 12775019
references: Intern Med. 1996 Dec;35(12):930-6
references: 9030989